Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Early accelerated approval for highly targeted cancer drugs.

× No keyword cloud information.

35 in total

Review 1. Moving molecular targeted drug therapy towards personalized medicine: issues related to clinical trial design.

Authors: Jaap Verweij; Maja de Jonge; Ferry Eskens; Stefan Sleijfer
Journal: Mol Oncol Date: 2012-02-16 Impact factor: 6.603

Review 2. Do immune checkpoint inhibitors need new studies methodology?

Authors: Roberto Ferrara; Sara Pilotto; Mario Caccese; Giulia Grizzi; Isabella Sperduti; Diana Giannarelli; Michele Milella; Benjamin Besse; Giampaolo Tortora; Emilio Bria
Journal: J Thorac Dis Date: 2018-05 Impact factor: 2.895

Review 3. Precision medicine needs randomized clinical trials.

Authors: Everardo D Saad; Xavier Paoletti; Tomasz Burzykowski; Marc Buyse
Journal: Nat Rev Clin Oncol Date: 2017-02-07 Impact factor: 66.675

Review 4. Drug development and clinical trials--the path to an approved cancer drug.

Authors: Eric H Rubin; D Gary Gilliland
Journal: Nat Rev Clin Oncol Date: 2012-02-28 Impact factor: 66.675

Review 5. Tumor control versus adverse events with targeted anticancer therapies.

Authors: Dorothy M K Keefe; Emma H Bateman
Journal: Nat Rev Clin Oncol Date: 2011-12-20 Impact factor: 66.675

Review 6. Cancer vaccines: what do we need to measure in clinical trials?

Authors: Alex Kudrin
Journal: Hum Vaccin Immunother Date: 2014-11-01 Impact factor: 3.452

7. Developing standards for breakthrough therapy designation in oncology.

Authors: Sandra J Horning; Daniel A Haber; Wendy K D Selig; S Percy Ivy; Samantha A Roberts; Jeff D Allen; Ellen V Sigal; Charles L Sawyers
Journal: Clin Cancer Res Date: 2013-05-29 Impact factor: 12.531

Review 8. Optimal design of trials to demonstrate the utility of genomically-guided therapy: Putting Precision Cancer Medicine to the test.

Authors: Rodrigo Dienstmann; Jordi Rodon; Josep Tabernero
Journal: Mol Oncol Date: 2014-07-15 Impact factor: 6.603

Review 9. The histological and biological spectrum of diffuse large B-cell lymphoma in the World Health Organization classification.

Authors: Madhu P Menon; Stefania Pittaluga; Elaine S Jaffe
Journal: Cancer J Date: 2012 Sep-Oct Impact factor: 3.360

10. Bayesian Two-stage Biomarker-based Adaptive Design for Targeted Therapy Development.

Authors: Xuemin Gu; Nan Chen; Caimiao Wei; Suyu Liu; Vassiliki A Papadimitrakopoulou; Roy S Herbst; J Jack Lee
Journal: Stat Biosci Date: 2014-12-04